A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Mar 2017
At a glance
- Drugs Lurasidone (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 01 Mar 2017 This trial was completed in Lithuania, according to European Clinical Trials Database.
- 21 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Jul 2016 Planned End Date changed from 1 Sep 2017 to 1 Apr 2018.